Table 2 Demographic characteristics and comorbidity status of the Matched PS Sub-Cohort at baseline
Low potency n (%) | High potency n (%) | Absolute standardized differences | |
|---|---|---|---|
119,857 (100) | 119,857 (100) | ||
Age, mean (SD)a | 64.6 (11.2) | 64.8 (11.2) | 0.021 |
Male sex | 59,690 (49.8) | 60,241 (50.3) | 0.009 |
At least 5 medical outpatient visits | 68,696 (57.3) | 69,017 (57.6) | 0.005 |
At least 1 hospitalisation | 29,527 (24.6) | 31,129 (26.0) | 0.031 |
Myocardial infarction | 8457 (7.1) | 8527 (7.1) | 0.002 |
Stroke | 3824 (3.2) | 4219 (3.5) | 0.018 |
Hypertension | 49,335 (41.2) | 50,719 (42.3) | 0.023 |
Hypercholesterolemia | 38,760 (32.3) | 38,887 (32.4) | 0.002 |
Peripheral vascular disease | 2374 (2.0) | 2691 (2.3) | 0.018 |
Congestive heart failure | 5412 (4.5) | 5852 (4.9) | 0.017 |
Coronary artery bypass graft | 1756 (1.5) | 1988 (1.7) | 0.016 |
Percutaneous coronary intervention | 5255 (4.4) | 4805 (4.0) | 0.019 |
Dispensation of loop diuretics | 7202 (6.0) | 7775 (6.5) | 0.020 |
Dispensation of calcium blockers | 26,878 (22.4) | 27,928 (23.3) | 0.021 |
Dispensation of beta-blockers | 35,805 (29.9) | 36,741 (30.7) | 0.017 |
Dispensation of angiotensin receptor blockers | 21,228 (17.7) | 21,776 (18.2) | 0.012 |
Dispensation of angiotensin converting enzyme inhibitors | 25,537 (21.3) | 26,484 (22.1) | 0.019 |
At least 5 different drugs dispensed | 69,608 (58.1) | 70,087 (58.5) | 0.008 |